AJOVY 225 MG / 1.5 ML
FREMANEZUMAB : 225 MG / 1.5 ML · DIN 02509474 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is AJOVY?
AJOVY 225 MG / 1.5 ML contains FREMANEZUMAB : 225 MG / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02509474, held by TEVA CANADA LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 01-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AJOVY used for?
Pr AJOVY® (fremanezumab solution for subcutaneous injection) is indicated for: the prevention of migraine in adults who have at least 4 migraine days per month. the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02509474 |
|---|---|
| Brand name | AJOVY |
| Generic / active ingredient | FREMANEZUMAB : 225 MG / 1.5 ML |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 225 MG / 1.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | N02CD03 FREMANEZUMAB |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Apr-2021 |
| Original market date | 2021-10-04 00:00:00 |
How is it stored and handled?
Remove AJOVY from the refrigerator. Prior to use, allow AJOVY to sit at room temperature for 30 minutes protected from direct sunlight. Do not warm by using a heat source such as hot water or a microwave. Do not use AJOVY if it has been at room temperature for 7 days or longer.
How is it supplied?
A carton of one 225 mg/1.5 mL (150 mg/mL) single-dose pre-filled syringe. A carton of one 225 mg/1.5 mL (150 mg/mL) single-dose prefilled autoinjector
What can be used instead?
Other Canadian products sharing ATC code N02CD03 FREMANEZUMAB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AJOVY | 225 MG / 1.5 ML | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02497859 |
Who else supplies FREMANEZUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FREMANEZUMAB appears in 20 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.